Company intelligence / Profile preview

IllumaRAS

Dripping Springs, TX, USA

Ownership: Private
Development stage: Other

Overview

IllumaRAS is a biomedical imaging company focused on the real-time visualization of mutant RAS cancer cells to improve surgical outcomes and diagnostic precision. The company develops metabolic agents and biomarkers that specifically target the unique metabolic signatures of RAS-mutant tumors, such as pancreatic ductal adenocarcinoma (PDAC). By illuminating these cells, IllumaRAS aims to enable "clean margins" during surgical resections and provide a platform for precision monitoring of cancer progression. Founded by experts in oncology and biopharmaceuticals, the company operates in close collaboration with Tezcat Biosciences to integrate diagnostic imaging with targeted therapeutics.

Therapeutic areas: Oncology
Modalities: Small moleculeMetabolic imaging agentsBiomarkers
Industry: Medical Imaging

Partnerships

Tezcat Biosciences

Beyond the preview

Go deeper on IllumaRAS.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IllumaRAS.

Explore the full profile